These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 31578100

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD.
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P.
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland.
    Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ.
    Eur J Neurol; 2013 May; 20(5):773-80. PubMed ID: 23278954
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S.
    J Headache Pain; 2017 Sep 06; 18(1):93. PubMed ID: 28879545
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness of Botox in Italian patients with chronic migraine.
    Ruggeri M.
    Neurol Sci; 2014 May 06; 35 Suppl 1():45-7. PubMed ID: 24867835
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 06; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study.
    Kollewe K, Gaul C, Gendolla A, Sommer K.
    J Headache Pain; 2021 Jun 02; 22(1):50. PubMed ID: 34078259
    [Abstract] [Full Text] [Related]

  • 16. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.
    Cephalalgia; 2019 Jul 02; 39(8):945-956. PubMed ID: 31112399
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
    Khalil M, Zafar HW, Quarshie V, Ahmed F.
    J Headache Pain; 2014 Sep 01; 15(1):54. PubMed ID: 25178393
    [Abstract] [Full Text] [Related]

  • 19. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.
    Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF.
    Headache; 2014 Sep 01; 54(10):1565-73. PubMed ID: 25298117
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.